A service to investigate the availability of human monoclonal antibodies against the desired antigen.
In addition to our human monoclonal antibody production service, we conduct an antibody acquisition feasibility assessment as a pre-test. Using the samples provided by our customers, we screen to determine whether antibodies against the desired target can be obtained. In this service, we evaluate the serum antibody titer against the desired antigen using serum provided simultaneously with PBMC, select three samples that are likely to yield antibodies, induce the proliferation of antibody-producing cells using the EBV method, and check the feasibility of antibody acquisition by examining the frequency of antibody-producing cells that bind to the target antigen using the culture supernatant. [Features] ■ Utilizes human peripheral blood lymphocytes owned by the customer ■ Screens for the feasibility of obtaining antibodies against the desired target *For more details, please refer to the catalog or feel free to contact us.
Inquire About This Product
basic information
【Service Overview】 This service investigates the availability of human monoclonal antibodies against your desired antigens using human peripheral blood lymphocytes (PBMC) owned by you. *For more details, please refer to the catalog or feel free to contact us.*
Price range
Delivery Time
Applications/Examples of results
For more details, please refer to the catalog or feel free to contact us.
catalog（1）
Download All Catalogs
Company information
iBeck Co., Ltd. is a company engaged in the manufacturing and sales of fully human antibodies for pharmaceuticals. By utilizing a unique method that does not rely on patents from Europe and the United States, we are able to produce fully human antibodies with fewer side effects. We have developed a technology to produce fully human antibodies from blood B lymphocytes, which are responsible for antibody production in the human body. Additionally, we provide these antibodies to companies involved in antibody pharmaceuticals and engage in joint development as alliance partners.